CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
SOHO 最新进展与后续问题 | 复发/难治性套细胞淋巴瘤的序贯治疗
英文原题：SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
查看英文原题
SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
套细胞淋巴瘤（MCL）是一种罕见的非霍奇金淋巴瘤，尽管治疗取得了进展，但仍无法治愈。临床病程可从惰性到侵袭性不等。随着对病理生理学理解的深入以及更多靶向治疗转向一线治疗，复发/难治性MCL的治疗正变得越来越不明确。本综述讨论了复发/难治性MCL患者当前和新兴治疗策略的证据，包括Bruton酪氨酸激酶抑制剂（BTKi）疗法以及双特异性T细胞衔接器和CAR-T 细胞等免疫疗法。
展开英文摘要原文
Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that, despite advances in treatment, remains incurable. Clinical courses can range from indolent to aggressive. As understanding of the pathophysiology improves and more targeted therapies shift to the frontline setting, treatment of relapsed and refractory MCL is becoming less defined.
This review discusses the evidence of current and emerging treatment strategies for patients with relapsed and refractory MCL, including Bruton tyrosine kinase inhibitor (BTKi) therapies and immunotherapies such as bispecific T-cell engagers and chimeric antigen receptor T-cells.
论文信息
- 作者
- Clement JM、Portell CA
- 第一作者单位
- Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.United States
- 通讯作者单位
- Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA. Electronic address: cp4ys@uvahealth.org.United States
- 文献类型
- 综述
- 期刊
- Clinical lymphoma, myeloma & leukemia2026 Apr
- 原文标识
- PubMed 41654478 · DOI 10.1016/j.clml.2026.01.008